Peptide Encyclopedia / CJC-1295
EncyclopediaCJC-1295 is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH) that raises GH and IGF-1. Human data come from small early-phase studies, it holds no FDA approval, and WADA bans it in sport. Below you'll find reported dosing, safety, and legal lines. Educational only, not medical advice.
| Also known as | CJC-1295 DAC, DAC:GRF, modified GRF (with Drug Affinity Complex) |
| Half-life | 5 |
| Regulatory status | NOT FDA-approved for any indication. |
NOT FDA-approved for any indication. CJC-1295 is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH). It is distributed only as an unapproved research chemical / compounded substance and is prohibited in sport. WADA lists GHRH analogues (explicitly including CJC-1295) under Prohibited List section S2.
CJC-1295 is an analog of GHRH(1-29) that binds and activates the GHRH receptor on anterior-pituitary somatotrophs, stimulating synthesis and pulsatile release of endogenous growth hormone, which in turn raises IGF-1. The 'DAC' (Drug Affinity Complex) variant incorporates a maleimidoproprionic acid group that covalently binds circulating albumin, greatly extending the duration of action compared with native GHRH or short-acting GHRH analogs. Pharmacokinetics (half-life Estimated 5.8 to 8.1 days for the DAC form (due to covalent albumin binding).): After a single subcutaneous injection of CJC-1295 (DAC), mean plasma GH increased 2- to 10-fold for 6 or more days and mean plasma IGF-1 increased 1.5- to 3-fold for 9-11 days, in dose-dependent fashion. The non-DAC 'modified GRF(1-29)' variant is much shorter-acting; the long half-life cited applies specifically to the DAC form.
Human data are limited to small, short-duration early-phase pharmacology studies. The Teichman 2006 study (two randomized, placebo-controlled, ascending-dose trials, 28 and 49 days) demonstrated sustained GH/IGF-1 elevation with no serious adverse reactions in healthy adults. There are no large, completed Phase 3 efficacy or long-term safety trials, and the agent is not approved for clinical use. Reported use: Reported (not approved) community and compounding-clinic use describes weekly or twice-weekly subcutaneous injection of the DAC form, or more frequent dosing of the non-DAC modified GRF(1-29), frequently combined with a ghrelin-receptor agonist such as ipamorelin. These regimens are not derived from FDA labeling or adequate controlled trials and are not validated or prescriptive. Reported only.
Long-term human safety is not established. Reported and class-based effects of sustained GH/IGF-1 elevation include fluid retention, arthralgias, paresthesias, carpal tunnel-type symptoms, reduced insulin sensitivity / elevated glucose, and theoretical concern for promoting growth of occult malignancies via IGF-1. Product identity and purity are unverified when obtained as a research chemical..
Active or suspected malignancy (theoretical IGF-1-mediated concern; no verified clinical source), Pregnancy and lactation (not studied).
Additive GH-releasing effect with ghrelin-receptor agonists (e.g., ipamorelin, MK-677), No verified source found for specific drug-drug interaction data
Log every dose and injection site, get the reconstitution and units math automatically, follow your cycle, and record how you feel, then export a provider report. CJC-1295 tracker, free to start.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. CJC-1295 may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
